Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(219)
•••
Post by rossline44on Feb 18, 2021 10:27am
184 Views
Post# 32595017

Cannabis potentials and innovations

Cannabis potentials and innovations
 
 
Sponsored Post
 
 
 
It was said that these various companies appear to be well positioned for growth in the commercial CB, MJ, and psychedelics sector based on extensive extraction and production experience. With a team of qualified experts in the space and cutting-edge CO² and ethanol extraction technology, the said companies could possibly be set for long-term strategic distribution and product innovation.
 
In some reports, these other companies facility located in Pemberton, BC appears to be built for EU-GMP certification and aims to produce high quality, high purity formulations on a commercial scale. Solvent free and scalable production also allows these companies to develop and deliver white-label formulations to service contract sales.
 
 
Check the disclaimer on profile and landing page.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities